Skip to main content
Indivior PLC logo

Indivior PLC — Investor Relations & Filings

Ticker · INDV ISIN · GB00BN4HT335 LEI · 213800V3NCQTY7IED471 IL Manufacturing
Open in API
Filings indexed 1,983 across all filing types
Latest filing 2025-02-27 Director's Dealing
Country GB United Kingdom
Listing IL INDV

About Indivior PLC

https://www.indivior.com/en

Indivior PLC is a global pharmaceutical company that develops, manufactures, and sells medicines to treat substance use disorders (SUD) and serious mental illnesses. The company's primary focus is on pioneering treatments for opioid use disorder (OUD), with a portfolio centered on buprenorphine-based prescription pharmaceuticals. Through its research and development efforts, Indivior aims to address the complex challenges of addiction and behavioral health by providing innovative, life-transforming therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS CLOSELY ASSOCIATED WITH THEM'. It details the purchase of Ordinary Shares by the Chair of the Company, Dr. David Wheadon. This type of filing, reporting insider transactions by directors/executives, directly corresponds to the definition of Director's Dealing (DIRS). The presence of the RNS Number and the closing statement confirming RNS as the news service further confirms it is a regulatory disclosure, but DIRS is the most specific category.
2025-02-27 English
JOSEPH CIAFFONI APPOINTED CHIEF EXECUTIVE OFFICER
Regulatory Filings
2025-02-27 English
Joseph Ciaffoni Appointed Chief Executive Officer
Board/Management Information Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number: 6154Y) from Indivior PLC, dated February 27, 2025. The core content announces the appointment of a new Chief Executive Officer (Joe Ciaffoni) and the stepping down of the previous CEO (Mark Crossley). This directly relates to changes in senior management and the board of directors. According to the definitions, 'Board/Management Information' (Code: MANG) covers the 'Announcement of changes in the company's board of directors or senior management.' Although it mentions the AGM regarding remuneration approval, the primary purpose is the CEO change announcement.
2025-02-27 English
HOLDING(S) IN COMPANY
Regulatory Filings
2025-02-25 English
Holding(s) in Company
Regulatory Filings Classification · 98% confidence The document is explicitly labeled with 'RNS Number' and contains the standard boilerplate text indicating it is provided by 'RNS, the news service of the London Stock Exchange.' The content itself is a 'TR-1: Standard form for notification of major holdings,' which details an acquisition of voting rights by Morgan Stanley, crossing a threshold. This type of mandatory disclosure to the market, distributed via the RNS system, falls under the general category for regulatory announcements that do not fit a more specific financial report type. Since it is a direct regulatory filing notification rather than an announcement *about* a report (like an ER or 10-K), the most appropriate classification is the general regulatory filing category.
2025-02-25 English
FDA APPROVAL OF SUBLOCADE LABEL CHANGES
Regulatory Filings
2025-02-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.